94. Pooled analysis of nirsevimab resistance through 150 days post dose in preterm and term infants

BACKGROUND: Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infection (LRTI) and hospitalization in infants. In two global pivotal placebo-controlled studies, nirsevimab, a monoclonal antibody to the RSV prefusion (F) protein with extended half-life, reduced medically...

Descripción completa

Detalles Bibliográficos
Autores principales: Abram, Michael E, Ahani, Bahar, Tabor, David E, Fernandes, Fiona, Wilkins, Deidre, Aksyuk, Anastasia A, Tuffy, Kevin M, Ji, Hong, Blaze, Christine, Brady, Tyler, Griffin, Pamela, Leach, Amanda, Villafana, Tonya L, Esser, Mark T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752125/
http://dx.doi.org/10.1093/ofid/ofac492.019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752125/
http://dx.doi.org/10.1093/ofid/ofac492.019

Ejemplares similares